

The Links between Brain Insulin Resistance and Alzheimer's Disease

Negar Khezri, Golnaz Yaghoubnezhadzanganeh, Amirreza Attarzadeh

Abstract—Type 2 Diabetes (T2DM) and Alzheimer's disease (AD) are two main health problems influencing millions of people in the world. Neuron loss and synaptic impairment that interfere with cognition and memory cause for the behavioral indications of AD. While it is now accepted that insulin has central neuromodulatory purpose, it was contemplated for many years that brain is insusceptible to insulin, involving its function in memory and learning, which are impaired in AD. The common characteristics of both AD and T2D are impaired insulin signaling, oxidative stress, the excitation of inflammatory pathways and unqualified glucose metabolism. This review summarizes how the recognition of these mechanisms may lead to the development of alternative therapeutic approaches. Here we summarize how the recognition of these mechanisms may lead to the development of alternative therapeutic approaches.

Keywords—Alzheimer's disease, diabetes, insulin resistance, neurodegenerative.

I. INTRODUCTION

AD only recently stopped being narrowly understood as a kind of neurodegenerative dementia associated with irregularly elevated levels of neurofibrillary tangles and amyloid b (Ab) plaques in the forebrain. The contemporary definition of AD is broader and includes the pathophysiological processes responsible for the gradual onset of dementia [1], [2]. Because only a small group of cases are the result of inherited genetic causes [3], the etiology and pathogenesis of intermittent, late-onset AD are still not fully understood. Some studies have drawn the conclusion that AD is a kind of diabetes specific to the brain [4], [5]. AD and T2DM are both age-related disorders of a largely coincidental nature [4]. On the basis of the over two decade-old Rotterdam study providing epidemiological evidence of a link between dementia and diabetes [6], even more evidence has been provided in support of a link between the two conditions. The risk of dementia is twice as high for patients with T2DM [7], [8]. A further association between diabetes and major depressive disorders has also been suggested to highlight the link between cognitive dysfunction and AD [9]. Elevated glycaemia increases the risk of dementia for non-diabetic individuals by 18% and has been linked to a reduced hippocampal volume and cognitive decline [10], [11]. The occurrence of AD has also been shown to have a positive

correlation with hyperinsulinemia and hyperglycemia [12], [13].

T2DM is a complicated metabolic disorder accompanied by high levels of glucose in the blood, the increased production of hepatic glucose, and the failure of pancreatic β -cells and insulin receptor to produce insulin [14]. T2DM is characterized by the resistance of peripheral organs to insulin, specifically muscle, the liver, and adipose tissues [15]. The two primary forms of diabetes, differentiated by etiology, are Type 1 diabetes, which involves the complete absence of insulin due to the autoimmune destruction of pancreatic β -cells, and T2DM, which is characterized by the combination of insulin resistance and decreased insulin secretion. Insulin performs both neurotropic and neuroprotective roles, as well as regulates synaptic plasticity in neurons [16], [17], making it an important means of modulating cognition (reviewed in [18]). Significant epidemiological evidence has also established a link between cognitive impairments and both types of diabetes [19]. Of note is the impairment of the pathway for signaling insulin in AD brains discovered by some studies [20], (reviewed in [21]) using a diversity of *in vivo* and *in vitro* experimental AD models, including non-transgenic and transgenic animal models [22]-[24]. Overall, these conclusions highlight insulin resistance as a common molecular mechanism linking AD and diabetes.

AD is one of the more common neurodegenerative disorders and involves neuronal and progressive memory loss, and the buildup of two poorly-soluble abnormal structures in the brain: amyloid plaques generated from Ab peptides, produced by the c-secretase complex and the b-site amyloid b precursor protein (APP) cleavage enzyme 1 (BACE1) from the sequential cleavage of the APP [25], and neurofibrillary tangles generated from the neuron-enriched, microtubule-associated protein, tau. The behavioral deficits attributed to AD are due to the synaptic dysfunction and death of memory and cognition-mediating neurons. The reduced function and viability of neurons are mediated by the biological and biochemical relationships between tau and Ab, particularly the soluble forms that serve as the foundation of plaque and tangles [26]. Some researchers have taken the view that the reduction in brain insulin signaling found in AD is proof that it is a form of T2D known as type 3 diabetes (T3D), especially when it is accompanied by evidence of altered CSF insulin [20], [27]. This conclusion is misrepresentative and the resistance to brain insulin found in AD cases is not T3D, although it has been posited that [28] neuronal insulin resistance syndrome is feature of AD.

Apart from the apparent metabolic implications, relatively

N. K. and G. Y. are with the Pharmacy Department, Eastern Mediterranean University, Famagusta, North Cyprus (e-mail: negarkhezri1371@gmail.com, ynzgolnaz@yahoo.com).

A. A. is with Economics Department, Eastern Mediterranean University, Famagusta, North Cyprus (e-mail: amirreza_attarzadeh@yahoo.com).

little was known about the relationships between specific AD phenotypes and reduced brain insulin signaling. Oddly, no proof of ectopic neuronal cell cycle re-entry (CCR) creating new neurons by dividing cells exists. Instead, CCR appears to be followed by neuron death accounting for as much as 90% of all AD-related neuron loss [29]. The resistance of the brain to insulin could indicate a lesion that significantly precluded the emergence of AD, or could alternatively occur after synaptic function and neuronal life-span have already been compromised by signaling processes. While the position of T2D as a risk factor for AD [30] presents insulin resistance in the brain as a causative factor, virtually nothing is known regarding the underlying causative mechanisms. The proceeding sections offer a review of contemporary research establishing a link between deficiencies in brain insulin signaling and the neurotoxic impact of Abs in AD. The apparent similarity between the pathways responsible for insulin dysfunction in AD and insulin resistance in diabetes provides the basis for a discussion of the molecular justification for the use of antidiabetic agents in AD treatment.

II. INSULIN SIGNALING

Insulin is a b-cell hormone produced by the pancreas to counteract elevated glucose levels from feeding. Insulin signaling physiologically begins when insulin is recognized and then bound to a transmembrane tyrosine kinase receptor, the insulin receptor (IR). The IRs, once activated, then phosphorylate a preserved group of adaptor proteins known as insulin receptor substrates 1 through 4 (IRS-1 through IRS-4) [31]. These IRSs then differentiate insulin stimulation into various unique pathways, the most important of which is the phosphoinositide 3-kinase (PI3K)/murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway, thereby permitting cells to be metabolically and transcriptionally reprogrammed [32]. The better-studied IRS-1 and IRS-2 substrates can be dissociated from the IR by undergoing inhibitory serine phosphorylation (pSer), which can also decrease tyrosine phosphorylation (pTyr) [32] consequently inhibiting downstream insulin signaling. Downstream insulin signaling can also be regulated by dephosphorylating tyrosine residues in IR and IRS-1 using the protein tyrosine phosphatase 1B (PTP1B) [33]. The central nervous system (CNS) is covered in enzyme insulin, IR and its substrates [34]. Brain insulin regulates body weight and food intake [35], as well as synaptic plasticity and neurotransmitter release, [36], thereby making it important for learning and memory [37]. Havrankova first highlighted the presence of IR in the brain, which has since been confirmed by others [38]. Insulin binds to the abundant but selectively-distributed insulin receptors (InsRs) in the brain. Studies involving rodents have found that the nerve terminals of crucial brain regions like the cerebellum, olfactory bulb, cerebral cortex, hypothalamus, and hippocampus contain the highest IR concentrations [18], [39], [40]. Insulin signaling is of particular importance for cognitive function in the hypothalamus and the limbic system, and is unaffected by changes in peripheral glucose [30]. While insulin is present in

the CNS, virtually none of it is locally produced. Insulin in the CNS is gotten from circulation and is able to cross the BBB due to a blood-to-brain saturable transport system [41]. The regulation of this transport system is performed by triglycerides, nitric oxide, hibernation, inflammatory events, glucose, obesity and the diabetic state independent of glucose [42]. Pancreatic b-cells synthesize most of the insulin that gets to the brain [43], while the brain synthesizes a small portion. The synthesis of preproinsulin 1 and 2 mRNA and insulin occurs in neuronal cells but not in glial cells [44]. The importance of insulin for the CNS goes beyond the metabolism of glucose. It has also been described as neuroprotective [45] and important for neuronal growth and survival [46], [47]. One recent study found an increased number of peripheral IR biomarkers in the hippocampus of AD patients without diabetes [28]. The impact of these studies is that the pathology of AD pathology is now understood to include defective brain insulin signaling [48].

A. Insulin Resistance

Peripheral metabolic disorders like T2D are characterized by decreased cellular responsiveness and insulin signaling caused by pro-inflammatory signaling and extended metabolic stress [49]. Known as insulin resistance, these pathological states exert a negative influence on cell capacity to sustain energy homeostasis. Remarkably, similar abnormalities are present in AD brains, including neuroinflammation and metabolic stress [22], [28], [50], [51]. The combined focus of the research was on whether neural changes in an AD brain are related to T2DM. Microvascular injury in the brain caused by T2DM can generate and/or accentuate the neuropathological symptoms of AD even if it is not directly linked to the AD neural substrate [52]. It is therefore conceivable that a similar mechanism can be used to explain peripheral insulin resistance in T2D and the diminished insulin signaling in AD brains. In fact, recent studies have established a link between diabetic peripheral insulin resistance and A β O-triggered neuropathogenic mechanisms [21], [22]. Hoyer et al. first suggested the idea of brain insulin resistance in AD about two decades ago [53] when they hypothesized that the reduction in brain glucose metabolism is due to the desensitization of neuronal IRs. While some [28], [54], but not all [55], studies found IR sensitivity to be reduced in the hippocampus and/or neocortex of AD brains, no conclusions have been drawn about the link to decreased brain glucose metabolism since insulin is known to have no independent effect on forebrain neuronal glucose absorption [18], [28] and they tested their hypotheses using intracerebroventricular (ICV) streptozotocin (STZ) in rodents [56]. STZ is a nitrosamide methyl nitroso urea associated with the C2 position of D glucose. N-nitrosourea is released once it has been metabolized and damages DNA by generating reactive oxygen types like nitric oxide, hydrogen peroxide, and superoxide [57]. The peripheral administration of STZ is a proven source of diabetes mellitus accompanied by moderate hepatic steatosis and neurodegeneration [58]. Insulin-producing cells like beta cells absorb the STZ in pancreatic islets [59] thereby damage the β -

cell. In fact, long-term cognitive behavioral deficits were observed in rats after the ICV injection of STZ, which decreases insulin by terminating pancreatic β -cells [60] as were neurodegenerative symptoms akin to those in AD without the added effect on insulin and peripheral glucose levels [54]. Insulin treatment could be used to prevent these deficits. Deficits in brain insulin signaling are partially responsible for the cognitive impairment in AD and diabetes [61]. These conclusions present IR as a common trigger in the development of both AD and T2DM. As such, sporadic AD (SAD) manifests itself as a form of T3D responsible for even more functional and structural brain changes. The available data render the application of this model to humans questionable as STZ is not widely available to humans. Conversely, the hypothesis posits STZ as a compound related to nitrosamine and Western societies have experienced an increase in exposure to environmental and food-related nitrosamines over recent decades [18]. The causal link between sub-mutagenic nitrosamine doses in food, e.g. N-nitrosodiethylamine (NDEA) and IR-related disorders has been experimentally proven [39]. Some studies have also shown that similar to STZ, even limited low-dose exposure to NDEA can cause visceral obesity, cognitive impairment, non-alcoholic steatohepatitis, T2DM, and AD-type neurodegeneration with peripheral and brain IR [61].

The discovery that Ab Oligomers (AbOs) provoked the rapid and wide-ranging redistribution of IRs into the somatic cytoplasm from the surfaces of cultured neuron dendrites through the entry of calcium into the dendrites via NMDA receptors provided one of the earliest insights into neuronal insulin insensitivity [62]. It is unlikely that this process is dependent on the synthesis and degradation of proteins as it occurs < 30 mins after exposing the neurons to AbOs; it is more likely a reflection of the increase in the IR endocytosis to exocytosis ratio. While it is not yet known which mechanism is responsible for the altered IR trafficking, the functional repercussion is that the IRs are sequestered from the extracellular space and cannot be accessed by the ligands to which they need to bind to begin insulin signaling. In addition to this IR sequestration, AbOs also decrease neuronal insulin signaling by inducing the secretion of aberrant tumor necrosis factor- α (TNF α) in cultures containing neurons, which are then bound to neuronal TNF α receptors and cause the stress kinase c-Jun N-terminal kinase (JNK) to activate [63]. The activated JNK causes IRS-1 serine phosphorylation (IRS-1pSer), thereby blocks insulin signaling and leads to peripheral insulin resistance [49]. Similarly, it was recently discovered that AbOs initiate the irregular activation of the TNF- α /JNK pathway and IRS-1 inhibition in principal hippocampal neurons [22], as well as in the hippocampi of cynomolgus monkeys subjected to ICV infusions of AbOs. The inhibition of IRS-1 was also proven in the brain of an AD model using a transgenic mouse [22]. Demonstrating the increased IRS-1pSer [22], [28] and activated JNK in AD brains postmortem was the most important step in ensuring these findings were clinically relevant. Microglia are a source of the TNF α behind this process. While AbOs are known to regularly target

neurons, they also affect microglia. TNF α was discovered to be secreted when primary microglia were exposed to AbOs, and in turn motivate the activation of JNK in primary neurons [64]. Since microglia are common components of primary neuron cultures, it is probable that some of the deficiencies in neuronal insulin signaling that are resulting from the exposure of primary neurons to AbOs, was triggered by TNF α derived from the microglia. Primary neuron cultures are also significantly populated with astrocytes, which are another potential source of TNF α in cultures treated with AbO [65].

III. IR REDUCTION IN AD

In an effort to determine if exposing neurons to AbOs *in vivo* influences insulin signaling in any other ways, western blotting and quantitative RT-PCR were used in measuring protein and IR mRNA in human brain tissue samples [20]. To test brain insulin resistance in AD, tests were run and due to diabetic conditions, cases with a history of diabetes were excluded [28], [66]. IRS-1 was the first molecule in this signaling pathway showing severe dysfunction, which, accordingly, seems to be a central factor in brain insulin resistance. The subsequent *ex vivo* stimulation studies [67] have shown that brain insulin resistance can develop early in AD, even in the absence of diabetes. In contrast, basal (i.e., not insulin stimulated) levels of activated or suppressed forms of those molecules below the IR were all increased in the same AD cases [28]. Unlike insulin resistance, IGF-1 resistance was severe, even at the level of the hormone receptor. The significance of this phenomenon remains to be determined.

A. Inflammation

Inflammation is an important characteristic of diabetes and AD is of vital importance for the pathogenesis of both disorders [49], [68] and has been posited as an auto-inflammatory disease [69]. Similar inflammatory processes are believed to take place in the brain, as well as surrounding tissue [40], [70]. Patients with T2D have been reported as having higher circulating levels of chemokines, cytokines, and acute-phase proteins [71], [72], as well as a reduced IL-1 receptor antagonist, higher level of b-cell IL-1 β , and local inflammation in the pancreatic islet, evidenced by the increased number of islet-associated macrophages [73]. AD has similarly been associated with a wide selection of inflammatory and immune pathways with post-mortem brains displaying significantly unregulated levels of pro-inflammatory chemokines, cytokines, and complement proteins. Impartial microarray research has also highlighted the increased expression of inflammation-related genes [74], [75]. Furthermore, a number of studies have genetically confirmed inflammation to be a powerful driver of AD pathology in mouse models based on a review by [76]. A methodical review of epidemiological studies provides evidence of an association between a reduced risk of AD and the consumption of non-steroidal anti-inflammatory drugs (NSAIDs) [77].

B. mTOR Deregulation in AD

In mammals, the target of rapamycin (mTOR) is a serine/threonine kinase. The functional forms of mTOR are integrated into one of two multi-protein, membrane-associated complexes: mTOR, mLST8 and raptor assemble in mTORC1 and mTOR, mLST8 and rictor in mTORC2 (reviewed in [78]). These two complexes are collectively responsible for how cells react to extracellular cues, such as growth factors, insulin, and nutrients like glucose and amino acids [79]. mTORC1 is primarily involved in controlling cell growth, while the major function of mTORC2 is survival and proliferation [80]. mTORC1 mainly functions by activating S6K and ATF4 and inhibition of 4EBP [81], while mTORC2 operates by activating SGK, PKC and Akt [82]. By testing cultured mouse neurons and transgenic mice, it was discovered that CCR requires the activation of both mTORC1 and mTORC2 by AbOs to proceed, and that mTORC1 activation is required for tau phosphorylation at S262 [83]. The AbO-facilitated activation of mTORC1 was discovered to be unconventional. While mTORC1 is typically activated at the lysosomal surface by other stimulants, thereby resulting in autophagy suppression [79], mTORC1 activation by AbOs occurs at the plasma membrane. Interestingly, this mislocalized mTORC1 activation is dependent on both the presence of tau and its mTORC1-dependent phosphorylation at S262 [83]. AbOs consequently instigate a toxic feedback loop between mTORC1 and tau, in which the former must induce tau phosphorylation at S262 to enable the latter gather at the plasma membrane, rather than the lysosomes. Tau phosphorylation at this site is likely catalyzed by S6K, rather than by mTORC1 directly; S6K is phosphor-activated by mTORC1 and phosphorylates tau at S262 [84]. Finally, it is possible to inhibit CCR by stimulating lysosomal mTORC1 using one of numerous experimental manipulations – like adding insulin to the culture medium [85] – while AbOs simultaneously activate mTORC1 at the plasma membrane. Collectively, research into AbO-induced neuronal CCR [83], [85] and AbO-induced insulin resistance [22], [74] suggests the toxic potential of AbOs to cause CCR and eventually neuron death is due to their ability to hinder neuronal responses to insulin. In fact, CCR can already be detected a few hours following the exposure of neuron to AbOs, suggesting that this occurrence is especially important in the pathogenesis of AD and could happen to individual neurons for many years during the disease's presymptomatic stages. Furthermore, the occurrence of neuronal CCR is independent of the incorporation of tau and Ab into tangles and plaques respectively, despite being initiated by Ab and proceeding using a tau-dependent mechanism.

C. Cerebroenergetic Failure

An unusual characteristic of AD is a significant reduction in the energy metabolism of brain areas that are affected [86]. Insulin's primary role in the CNS is the stimulation of glucose uptake into tissues using glucose transporters (GLUTs 1–8), [87]. The synthesis of numerous neurotransmitters responsible for cognitive function and synaptic plasticity, such as

glutamate, GABA, dopamine, acetylcholine, amongst others, requires the use of glucose. In contrast to the normal ageing process where the cerebral energy pool decreases only slightly, sporadic AD impairs both the production and utilization of energy [88]. Seemingly hypothetical, describing AD as “diabetes mellitus of the brain” is nonetheless interesting in light of the growing body of evidence of similarities in the biochemical irregularities observed in glucose hypo-metabolism AD and T2DM [89]. Furthermore, the IR-induced hyperglycemia observed in T2DM is also attributed to glucose hypo-metabolism and energy failure [90]. These findings point to a shared link in the pathogenic molecular mechanisms of AD and T2DM.

D. Oxidative Stress

The emergence of mitochondrial dysfunction and oxidative stress is partly caused by cerebroenergetic failure [91]. Oxidative stress is the result of an imbalance between the antioxidant capacity of the cell and the amount of free radicals generated by metabolic activity, thereby causing lipids, nucleotide, proteins, and their damaged biological activities to be attacked and eventual cell death. The disproportionate production of free radicals can be caused by hyperglycemia [92]. Mitochondrial dysfunction enhances the generation of ROS, decreases the production of ATP, and impairs the functioning of the electron transport chain. A substantial body of experimental and clinical evidence exists showing enhanced oxidative stress in both T1D and T2D [93] as a part of the diabetic neuropathy [92], [94]. AD brains also display a heightened expression of the pro-oxidant enzymes responsible for catalyzing the introduction of reactive nitrogen (RNS) and oxygen species (ROS) like nitric oxide synthase (NOS) and NADPH oxidase (NOX). The observations that the formation of Ab plaque precedes oxidative damage [95] and the upsurge in RNS corresponds to the beginning of Ab deposition observed in a transgenic AD mouse model [96] led researchers to hypothesize that enhanced Ab production can be triggered by oxidative stress. This contention is backed by sufficient experiential evidence illustrating how the expression of b-secretase and c-secretase is regulated by oxidative stress, which also promotes Ab production and the amyloidogenic processing of APP [97], [98]. It is noteworthy that recent studies have reported the possibility of Ab interaction with mitochondrial proteins, disrupting the electron transport chain, promoting mitochondria dysfunction, and the generation of ROS, thereby supporting a vicious cycle [99]. Furthermore, oxidative stress can increase tau hyperphosphorylation and ensuing tangle formation by transforming and disturbing peptidyl-prolyl cis–trans isomerase Pin1 [100]. Redox proteomics analysis has been used to identify other oxidatively-modified proteins in the AD brain hypothetically relevant to the pathogenesis of AD [101].

E. Tau Tangle Formation

The role of the unusual tau phosphorylation in the pathophysiology of AD was identified in the 1980s [102]. The folding of tau protein with tubulin is generally used to enhance

vehicular transport and microtubule formation. When hyper phosphorylated, tau becomes insoluble and becomes less compatible with microtubules, resulting in the formation of neurofibrillary tangles (NFTs) [103]. NFTs are a hyper phosphorylated and cumulative form of tau protein, the accumulation and pathology of which correlate most significantly with dementia in AD [104]. In fact, different animal AD, obesity, and T2DM models with a reduction in insulin signaling have been found to have higher levels of insoluble hyper phosphorylated tau and the deposition of NFTs [105], [106]. As a result, a reduction in insulin signaling appears to encourage NFT formation, give on to the loss of synaptic connections, interrupt neuronal cytoskeletal networks and axonal transport, and incremental neurodegeneration. Collectively, these conclusions insinuate that the onset of AD and its severity are heightened by IR, particularly in cases with a tendency towards tau pathology [40].

IV. ANTI-DIABETIC DRUGS IN AD

Most proposed approaches to AD treatment till date have resulted in disappointing failures in clinical trials [107]. Experimental evidence is increasingly establishing the different links between the pathogenic mechanisms of AD and T2DM/metabolic diseases, and the vital role of insulin in the growth and development of neurons rationalizes the use of anti-diabetic agents in modern AD therapies. Similarly, a number of potentially successful insulin-based AD treatment strategies have also been developed [21]. Insulin signaling diminishes overtime as part of the ageing process [108]. Since age is an important AD risk factor, this suggests that patients with AD might benefit from the restoration of insulin signaling.

Because the systemic administration of insulin has a problematic impact on the periphery, intranasal insulin delivery provides a seemingly harmless and efficient alternative method of increasing concentrations of CSF insulin without affecting the levels of systemic insulin and glucose. Particularly interesting is the discovery that the intranasal administration of insulin, a preferred method of CNS delivery [109], enhances memory function, such as in the delayed word recall test for young adults with a normal cognitive capacity [110], improves verbal memory in subjects with mild cognitive impairment (MCI) and AD [111], enhances declarative memory and selective attention performance in patients with early-onset AD, and also implying an increase in A β clearance and reduced amyloid pathology. Some studies, however, have suggested that only patients with ApoE- ϵ 4-negative genotypes can be effectively treated using intranasal insulin [112].

When the number of surface IRs is reduced in the later stages of AD, insulin can be used to stimulate alternative receptors (e.g., insulin-like growth factor 1 (IGF-1) receptors) and continue to improve the deficiencies caused by AD. Regardless, the evidence provided by these studies suggests that intranasal insulin could still be used in the treatment of patients with early AD and MCI. Alternative strategies could also be employed, such as using insulin sensitizers like

peroxisome proliferator-activated receptors [(PPARs) PPAR- γ] and glucagonlike peptide-1 (GLP-1) agonists, both known to have therapeutic benefits similar to intranasal insulin. PPARs are a group of nuclear receptors responsible for regulating how the genes used in lipid and glucose metabolism are transcribed. Clinical tests of pioglitazone and rosiglitazone – PPAR- γ agonists in T2DM, MCI, or AD patients have generated mixed results. While this shortcoming hindered any further development, this position needs to be reevaluated [113]. Incretins, glucose-dependent insulinotropic peptide (GIP) and GLP-1, are a family of GI hormones capable of affecting how the entire body utilizes glucose [114]. GLP-1R agonists were recently posited as an additional/alternative therapeutic approach to insulin-based AD therapies. GLP-1 analogs or mimetics are a top choice amongst drugs marketed for development as AD therapeutic agents [115]. Glucagon-like peptide 1 receptor (GLP-1R) agonists have been identified as activating pathways commonly used for insulin signaling and facilitate the plasticity of hippocampal synapses, cognition, and cell survival [116], [117]. GLP-1 analogs such as Exendin-4 and liraglutide which are authorized for T2D treatment are stable in blood and represent well brain permeation [118], [119]. The impairment of insulin signaling in hippocampal neurons due to AbO was recently discovered to be blocked by Exendin-4 [22]. It also facilitated the restoration of diminished brain insulin signaling in a transgenic mouse AD model, thereby mitigating the accumulation of Ab and improving cognition [22]. More significantly, liraglutide appears to offset memory deficiencies in mice induced by Ab [120], minimize neuropathology, and improve cognition in AD transgenic mice [121]. The full range of cellular mechanisms used by the activation of GLP-1R to facilitate neuroprotection and enhance cognition has yet to be accounted for. Consequently, the activation of GLP-1R could provide a new approach to resensitizing diminished insulin signaling in the brain and to halt or even prevent neurodegeneration in AD entirely. Experimental studies have concluded that GLP-1R agonist enhances cognitive function and mitigates the formation of A β and tau tangles in various AD animal models [122].

V. CONCLUSION

In conclusion, the establishment of a molecular link between AD and diabetes will have important ramifications for understanding the underlying mechanisms responsible for neuronal dysfunction in AD. This review has highlighted the importance of impaired insulin signaling, inflammation, oxidative stress and mitochondria dysfunction. The recently discovered pathophysiological and clinical similarities between diabetes and AD highlight the potential cognitive benefits of antidiabetic agents. This proposition is supported by evidence showing that AbOs (increasingly recognized as important synaptotoxins in AD) use proinflammatory mechanisms to interrupt normal insulin signaling in the brain in a manner similar to the experience of peripheral tissue in diabetes. Insulin signaling in the brain can be stimulated to counteract the resultant cellular stress and synapse

dysfunction, using either insulin or an antidiabetic drug like a GLP-1R agonist. The inability of various T2D treatments to reduce the risk of AD or enhance cognition in AD dementia indicates that merely reducing the level of peripheral insulin resistance is an ineffective strategy. This is especially true for treatments involving the peripheral administration of insulin, sulfonylureas, metformin, and thiazolidinediones like rosiglitazone and pioglitazone [123], [124].

REFERENCES

- [1] Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH, "Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease", *Alzheimers Dement*, 2011, pp. 257-62.
- [2] Sperling, Reisa A., Paul S. Aisen, Laurel A. Beckett, David A. Bennett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo et al. "Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." *Alzheimer's & dementia* 7, no. 3, 2011, pp. 280-92.
- [3] Van Es MA, van den Berg LH, "Alzheimer's disease beyond APOE", *Nat Genet*, 2009, pp. 1047-76.
- [4] Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. "Diabetes mellitus and Alzheimer's disease: shared pathology and treatment", *Br J Clin Pharmacol*, 2011, pp. 365-76.
- [5] de la Monte SM, Wands JR, "Alzheimer's disease is type 3 diabetes: evidence reviewed", *J Diabetes Sci Technol*, 2008, pp. 1101-13.
- [6] Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. "Diabetes mellitus and the risk of dementia: the Rotterdam Study," *Neurology*, vol. 53, 1999, pp. 1937-42.
- [7] Huang CC, Chung CM, Leu HB, Lin LY, Chiu CC, Hsu CY, Chiang CH, Huang PH, Chen TJ, Lin SJ, Chen JW, Chan WL, "Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study", *PLoS One*, vol. 9, 2014, pp. 80795.
- [8] Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y, "Glucose tolerance status and risk of dementia in the community: the Hisayama Study", *Neurology*, vol. 77, 2011, pp. 1126-34.
- [9] Cha DS, Carvalho AF, Rosenblat JD, Ali MM, McIntyre RS, "Major depressive disorder and type II diabetes mellitus: mechanisms underlying risk for Alzheimer's disease", *CNS Neurol. Disord. Drug Targets*, vol. 13, 2014, pp. 1740-49.
- [10] Crane PK, Walker R, Hubbard RA, et al, "Glucose levels and risk of dementia", *N. Engl. J. Med*, vol. 369, 2013, pp. 540-48.
- [11] Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Flöel A, "Higher glucose levels associated with lower memory and reduced hippocampal microstructure", *Neurology*, vol. 81, 2013, pp. 1746-52.
- [12] Baker LD, Cross DJ, Minooshima S, Belongia D, Watson GS, Craft S, "Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes", *Arch. Neurol*, vol. 68, 2011, pp. 51-57.
- [13] T. Matsuzaki, K. Sasaki, Y. Tanizaki, J. Hata, K. Fujimi, Y. Matsui, A. Sekita, S.O. Suzuki, S. Kanba, Y. Kiyohara, T. Iwaki, "Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study", *Neurology*, vol. 75, 2010, pp. 764-70.
- [14] Butterfield, D. Allan, Fabio Di Domenico, and Eugenio Barone, "Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain." *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1842, no. 9, 2014, pp. 1693-1706.
- [15] Bonadonna RC, De Fronzo RA, "Glucose metabolism in obesity and type 2 diabetes", *Diabète métabolisme*, vol. 17, 1991, pp. 112-35.
- [16] Chiung-Chun Huang, Cheng-Che Lee, Kuei-Sen Hsu, "An investigation into signal transduction mechanisms involved in insulin-induced long-term depression in the CA1 region of the hippocampus", *J. Neurochem*, vol. 89, 2004, pp. 217-31.
- [17] Lee, Cheng-Che, Chiung-Chun Huang, Mei-Ying Wu, and Kuei-Sen Hsu, "Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt/mammalian target of rapamycin signaling pathway", *J. Biol. Chem.*, vol. 280, 2005, pp. 18543-50.
- [18] WQ Zhao, H Chen, MJ Quon, DL Alkon, "Insulin and the insulin receptor in experimental models of learning and memory", *Eur. J. Pharmacol*, vol. 490, 2004, pp. 71-81.
- [19] Brands, Augustina MA, Geert Jan Biessels, Edward HF De Haan, L. Jaap Kappelle, and Roy PC Kessels, "The effects of type 1 diabetes on cognitive performance: a meta-analysis", *Diabetes Care*, vol. 28, 2005, pp. 726-35.
- [20] Steen, Eric, Benjamin M. Terry, Enrique J Rivera, Jennifer L. Cannon, Thomas R. Neely, Rose Tavares, X. Julia Xu, Jack R. Wands, and Suzanne M. de la Monte, " Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease is this type 3 diabetes", *J. Alzheimers Dis.*, vol. 7, 2005, pp. 63-80.
- [21] S. Craft, "Alzheimer disease: insulin resistance and AD dextending the translational path", *Nat. Rev. Neurol.*, vol. 8, 2012, pp. 360-2.
- [22] Bomfim, Theresa R., Leticia Forny-Germano, Luciana B. Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A. Silverman et al. "An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Ab oligomers," *J. Clin. Invest.* vol. 122, 2012, pp. 1339-53.
- [23] Lourenco, Mychael V., Julia R. Clarke, Rudimar L. Frozza, Theresa R. Bomfim, Leticia Forny-Germano, André F. Batista, Luciana B. Sathler et al. "TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeyes", *cell metab*, vol. 18, 2013, pp. 831-43.
- [24] Takeda, Shuko, Naoyuki Sato, Kozue Uchio-Yamada, Kyoko Sawada, Takanori Kunieda, Daisuke Takeuchi, Hitomi Kurinami, Mitsuru Shinohara, Hiromi Rakugi, and Ryuichi Morishita, "Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes", *Proceedings of the National Academy of Sciences USA*, 2010, pp.7036-7041.
- [25] X Sun, K Bromley-Brits, W Song, "Regulation of beta-site APP cleaving enzyme 1 gene expression and its role in Alzheimer's disease", *J Neurochem*, vol. 120, 2012, pp. 62-70.
- [26] G. Bloom, "Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis", *JAMA neurol*, vol. 71, 2014, pp. 505-8.
- [27] M Suzanne, "Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease", *Drugs*, vol. 72, 2012, pp. 49-66.
- [28] Talbot, Konrad, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P. Bakshi, Andres Stucky, Robert L. Fuino et al. "Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline", *J Clin Invest*, vol. 122, 2012, pp. 1316-38.
- [29] T Arendt, MK Brückner, B Mosch, A Lösche, "Selective cell death of hyperploid neurons in Alzheimer's disease", *Am. J. Pathol.*, vol. 177, 2010, pp. 15-20.
- [30] S. Craft, "Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment", *Curr. Alzheimer Res.*, vol. 4, 2007, pp. 147-152.
- [31] Z Cheng, Y Tseng, MF White, "Insulin signaling meets mitochondria in metabolism", *Trends Endocrinol Metab*, vol. 21, 2010, pp. 589-98.
- [32] MF White, "Insulin signaling in health and disease", *Science*, vol. 302, 2003, pp. 1710-1.
- [33] Goldstein, Barry J., Anna Bittner-Kowalczyk, Morris F. White, and Mark Harbeck, "Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by proteintyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein", *J. Biol. Chem.*, vol. 275, 2000, pp. 4283-9.
- [34] Adamo M, Raizada MK, LeRoith D., "Insulin and insulin-like growth factor receptors in the nervous system", *Mol Neurobiol*, 1989, pp. 71-100.
- [35] Baskin, Denis G., Dianne Figlewicz Lattemann, Randy J. Seeley, Stephen C. Woods, Daniel Porte Jr, and Michael W. Schwartz, " Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight", *Brain Res*, vol. 848, 1999, pp. 114-23.
- [36] G. Ahmadian, W. Ju, L. Liu, M. Wyszynski, S. Hyoung Lee, A. W. Dunah, C. Taghibiglou, Y. Wang, J. Lu, T. P. Wong, M. Sheng, and Y. T. Wang, "Tyrosine phosphorylation of GluR2 is required for insulin stimulated AMPA receptor endocytosis and LTD", *EMBO J*, 2004, pp. 1040-50.
- [37] WQ Zhao, DL Alkon, "Role of insulin and insulin receptor in learning and memory," *Mol Cell Endocrinol*, vol. 177, 2001, pp. 125-34.
- [38] Havrankova, J., Roth, J., Brownstein, M., "Insulin receptors are widely distributed in the central nervous system of the rat", *Nature* 272, no. 5656, 1978, pp. 827.

- [39] M. Salkovic-Petrisic, S Hoyer "Central Insulin Resistance as a Trigger for Sporadic Alzheimer-like Pathology: An Experimental Approach", Springer, 2007, pp. 217-33.
- [40] Rani, Vanita, Rahul Deshmukh, Priya Jaswal, Puneet Kumar, and Jitender Bariwal, "Alzheimer's disease: Is this a brain specific diabetic condition", *physiology and behavior*, 2016, pp. 259-267.
- [41] Banks, William A., Shinya Dohgu, Jessica L. Lynch, Melissa A. Fleegal-DeMotta, Michelle A. Erickson, Ryota Nakaoke, and Than Q. Vo, "Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the blood-brain barrier", *Endocrinology*, vol. 149, 2008, pp. 1514-23.
- [42] WA Banks, JB Jaspán, W Huang, AJ Kastin, "Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin", *Peptides*, vol. 18, 1997, pp. 1423-29.
- [43] W. Banks, "The source of cerebral insulin," *Eur. J. Pharmacol.* 2004.
- [44] Schechter, Ruben, and Michael Abboud. "Neuronal synthesized insulin roles on neural differentiation within fetal rat neuron cell cultures", *Developmental Brain Research*, 2001, pp. 41-49.
- [45] Pang, Yi, Shuying Lin, Camilla Wright, Juying Shen, Kathleen Carter, Abhay Bhatt, and L-W. Fan, "Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats", *Neuroscience*, vol. 318, 2016, pp. 157-65.
- [46] Cardoso, Susana, Sónia Correia, Renato X. Santos, Cristina Carvalho, Maria S. Santos, Catarina R. Oliveira, George Perry, Mark A. Smith, Xiongwei Zhu, and Paula I. Moreira, "Insulin is a two-edged knife on the brain", *J. Alzheimer's Dis.*, vol. 18, 2009, pp. 483-507.
- [47] D Dávila, I Torres-Aleman, "Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling", *Mol. Biol. Cell*, vol. 19, 2008, pp. 2014-25.
- [48] F.G. De Felice, "Alzheimer's disease and insulin resistance: translating basic science into clinical applications", *J. Clin. Invest.*, vol. 123, 2013, pp. 531-9.
- [49] MF Gregor, GS Hotamisligil, "Inflammatory mechanisms in obesity," *Annu Rev Immunol.* vol. 29, 2011, pp. 415-45.
- [50] Ledo, J. H., E. P. Azevedo, J. R. Clarke, F. C. Ribeiro, C. P. Figueiredo, D. Foguel, F. G. De Felice, and S. T. Ferreira, "Amyloid- β oligomers link depressive-like behavior and cognitive deficits in mice", *Molecular psychiatry*, vol 18, no. 10, 2013, pp. 1053.
- [51] Yoon, Sung Ok, Dong Ju Park, Jae Cheon Ryu, Hatice Gulcin Ozer, Chhavy Tep, Yong Jae Shin, Tae Hee Lim et al. "JNK3 perpetuates metabolic stress induced by A β peptides", *Neuron*, vol 75, no. 5, 2012, pp. 824-37.
- [52] G.N. Brito, "Exercise and cognitive function: a hypothesis for the association of type II diabetes mellitus and Alzheimer's disease from an evolutionary perspective," *Diabetol. Metab. Syndr.* 2009.
- [53] N Henneberg, S Hoyer, "Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)", *Arch Gerontol Geriatr.* vol. 21, 1995, pp. 63-74.
- [54] Rivera, Enrique J., Alison Goldin, Noah Fulmer, Rose Tavares, Jack R. Wands, and Suzanne M. de la Monte, "Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine", *Journal of Alzheimer's Disease*, vol 8, no. 3, 2005, pp. 247-268.
- [55] Frölich, L., D. Blum-Degen, H-G. Bernstein, S. Engelsberger, J. Humrich, S. Lauffer, D. Muschner et al. "Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease", *Journal of neural transmission*, vol 105, no. 4-5, 1998, pp. 423-38.
- [56] Lester-Coll, Nataniel, Enrique J. Rivera, Stephanie J. Soscia, Kathryn Doiron, Jack R. Wands, and Suzanne M. de la Monte, "Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease", *Journal of Alzheimer's Disease*, vol 9, no. 1, 2006, pp. 13-33.
- [57] A.D. Bolzán, M.S. Bianchi, "Genotoxicity of streptozotocin", *Mutat. Res.*, 2002, pp. 121-34.
- [58] T. Szkudelski, "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas", *Physiol. Res.*, 2001, pp. 537-46.
- [59] J. M. Suzanne, "Alzheimer's disease is type 3 diabetes—evidence reviewed," *Journal of Diabetes Science and Technology*, 2008, pp. 1101-13.
- [60] Grünblatt, Edna, Melita Salkovic-Petrisic, Jelena Osmanovic, Peter Riederer, and Siegfried Hoyer, "Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein", *Journal of neurochemistry*, vol 101, no. 3, 2007, pp. 757-70.
- [61] Sato, Naoyuki, Shuko Takeda, Kozue Uchio-Yamada, Hironori Ueda, Tomomi Fujisawa, Hiromi Rakugi, and Ryuichi Morishita, "Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential", *Current aging science*, vol 4, no. 2, 2011, pp. 118-27.
- [62] Zhao, Wei-Qin, Fernanda G. De Felice, Sara Fernandez, Hui Chen, Mary P. Lambert, Michael J. Quon, Grant A. Krafft, and William L. Klein, "Amyloid beta oligomers induce impairment of neuronal insulin receptors", *The FASEB Journal*, vol 22, no. 1, 2008, pp. 246-60.
- [63] Hirosumi, Jiro, Gürol Tuncman, Lufen Chang, Cem Z. Görgün, K. Teoman Uysal, Kazuhisa Maeda, Michael Karin, and Gökhan S. Hotamisligil, "A central role for JNK in obesity and insulin resistance", *Nature*, vol 420, no. 6913, 2002, pp. 333.
- [64] Bhaskar, Kiran, Nicole Maphis, Guixiang Xu, Nicholas H. Varvel, Olga N. Kokiko-Cochran, Jason P. Weick, Susan M. Staugaitis et al. "Microglial derived tumor necrosis factor- α drives Alzheimer's disease-related neuronal cell cycle events", *Neurobiology of disease*, vol 62, 2014, pp. 273-85.
- [65] Carrero, I., M. R. Gonzalo, B. Martin, J. M. Sanz-Anquela, J. Arevalo-Serrano, and A. Gonzalo-Ruiz, "Oligomers of beta-amyloid protein (A β 1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain", *Experimental neurology*, vol 236, no. 2, 2012, pp. 215-27.
- [66] Wang, Hoau-Yan, Kalindi Bakshi, Maya Frankfurt, Andres Stucky, Marissa Goberdhan, Sanket M. Shah, and Lindsay H. Burns, "Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A", *Journal of Neuroscience*, vol 32, no. 29, 2012, pp.9773-84.
- [67] Espinosa, Ana, Montserrat Alegret, Sergi Valero, Georgina Vinyes-Junqué, Isabel Hernández, Ana Mauleón, Maitée Rosende-Roca et al. "A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved", *Journal of Alzheimer's Disease*, vol 34, no. 3, 2013, pp.769-80.
- [68] Clark, Ian, Craig Atwood, Richard Bowen, Gilberto Paz-Filho, and Bryce Vissel, "Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales", *Pharmacological reviews*, vol 64, no. 4, 2012, pp. 1004-26.
- [69] Donath, Marc Y., and Steven E. Shoelson, "Type 2 diabetes as an inflammatory disease", *Nature Reviews Immunology*, vol 11, no. 2, 2011, pp. 98.
- [70] Najem, Dema, Michelle Bamji-Mirza, Nina Chang, Qing Yan Liu, and Wandong Zhang, "Insulin resistance, neuroinflammation, and Alzheimer's disease." *Reviews in the Neurosciences*, vol 25, no. 4, 2014, pp. 509-25.
- [71] Herder, C., T. Illig, W. Rathmann, S. Martin, B. Haastert, S. Müller-Schölze, R. Holle et al. "Inflammation and type 2 diabetes: results from KORA Augsburg," *Das Gesundheitswesen*, vol 67, no. S 01, 2005, pp. 115-21.
- [72] Herder, Christian, Eric J. Brunner, Wolfgang Rathmann, Klaus Strassburger, Adam G. Tabák, Nanette C. Schloot, and Daniel R. Witte, "Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The Whitehall II study", *Diabetes care*, vol 32, no. 3, 2009, pp. 421-3.
- [73] Ehses, Jan A., Aurel Perren, Elisabeth Eppler, Pascale Ribaux, John A. Pospisilik, Ranit Maor-Cahn, Xavier Gueripel et al. "Increased number of islet-associated macrophages in type 2 diabetes", *Diabetes*, vol 56, no. 9, 2007, pp. 2356-70.
- [74] Blalock, E. M., K-C. Chen, A. J. Stromberg, C. M. Norris, I. Kadish, S. D. Kraner, N. M. Porter, and P. W. Landfield, "Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation", *Ageing research reviews*, vol 4, no. 4, 2005, pp. 481-512.
- [75] Katsel, Pavel L., Kenneth L. Davis, and Vahram Haroutunian, "Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease", 2005, pp. 41-82.
- [76] Wyss-Coray, Tony, "Inflammation in Alzheimer disease: driving force, bystander or beneficial response", *Nature medicine*, vol 12, no. 9, 2006, pp. 1005.
- [77] Szekeley, Christine A., Jennifer E. Thorne, Peter P. Zandi, Mats Ek, Erick Messias, John CS Breitner, and Steven N. Goodman, "Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review", *Neuroepidemiology*, vol 23, no. 4, 2004, pp. 159-69.

- [78] Wullschleger, Stephan, Robbie Loewith, and Michael N. Hall, "TOR signaling in growth and metabolism", *cell* 124, no. 3, 2006, pp. 471-84.
- [79] Zoncu, Roberto, Alejo Efeyan, and David M. Sabatini, "mTOR: from growth signal integration to cancer, diabetes and ageing", *Nature reviews Molecular cell biology*, vol 12, no. 1, 2011, pp. 21.
- [80] Loewith, Robbie, Estela Jacinto, Stephan Wullschleger, Anja Lorberg, José L. Crespo, Débora Bonenfant, Wolfgang Oppliger, Paul Jenoe, and Michael N. Hall, "Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control", *Molecular cell*, vol 10, no. 3, 2002, pp. 457-68.
- [81] Ben-Sahra, Issam, Gerta Hoxhaj, Stéphane JH Ricoult, John M. Asara, and Brendan D. Manning, "mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle", *Science*, vol 351, no. 6274, 2016, pp. 728-33.
- [82] Hresko, Richard C., and Mike Mueckler, "mTOR· RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes", *Journal of Biological Chemistry*, vol 280, no. 49, 2005, pp. 40406-16.
- [83] Norambuena, Andrés, Horst Wallrabe, Lloyd McMahon, Antonia Silva, Eric Swanson, Shahzad S. Khan, Daniel Baerthlein et al. "mTOR and neuronal cell cycle reentry: how impaired brain insulin signaling promotes Alzheimer's disease." *Alzheimer's & Dementia*, vol 13, no. 2, 2017, pp. 152-67.
- [84] Pei, Jin-Jing, Cecilia Björkdahl, Haiyan Zhang, Xinwen Zhou, and Bengt Winblad, "p70 S6 kinase and tau in Alzheimer's disease", *Journal of Alzheimer's Disease*, vol 14, no. 4, 2008, pp. 385-92.
- [85] Seward, Matthew E., Eric Swanson, Andrés Norambuena, Anja Reimann, J. Nicholas Cochran, Rong Li, Erik D. Roberson, and George S. Bloom, "Amyloid- β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease", *J Cell Sci*, 2013, jcs-1125880.
- [86] Hallschmid, M., and B. Schultes, "Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders", *Diabetologia*, vol 52, no. 11, 2009, pp. 2264-9.
- [87] Bosco, Domenico, Antonietta Fava, Massimiliano Plastino, Tiziana Montalcini, and Arturo Pujia, "Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis", *Journal of cellular and molecular medicine*, vol 15, no. 9, 2011, pp. 1807-21.
- [88] Rapoport, Stanley I., Kimmo Hatanpää, Daniel R. Brady, and Krish Chandrasekaran, "Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease", *Neurodegeneration*, vol 5, no. 4, 1996, pp. 473-6.
- [89] M. Smith, "Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link," *Diabetologia*, 1996, p. 247.
- [90] DeFronzo, Ralph A., and Devjit Tripathy, "Skeletal muscle insulin resistance is the primary defect in type 2 diabetes", *Diabetes care*, vol 32, no. suppl 2, 2009, pp. S157-63.
- [91] A. Nunomura, G. Perry, M. A. Pappolla, R. Wade, K. Hirai, S. Chiba and Mark A., "RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease", *J. Neuroscience*, 1999, pp. 1959-64.
- [92] Vincent, Andrea M., James W. Russell, Phillip Low, and Eva L. Feldman, "Oxidative stress in the pathogenesis of diabetic neuropathy", *Endocrine reviews*, vol 25, no. 4, 2004, pp. 612-28.
- [93] Rösen, P., P. P. Nawroth, Gr King, W. Möller, H-J. Tritschler, and L. Packer, "The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society." *Diabetes/metabolism research and reviews*, vol 17, no. 3, 2001, pp. 189-212.
- [94] Russell, James W., Alison Berent-Spilson, Andrea M. Vincent, Catherine L. Freimann, Kelli A. Sullivan, and Eva L. Feldman, "Oxidative injury and neuropathy in diabetes and impaired glucose tolerance." *Neurobiology of disease*, vol 30, no. 3 (2008), pp. 420-9.
- [95] Resende, Rosa, Paula Isabel Moreira, Teresa Proença, Atul Deshpande, Jorge Busciglio, Cláudia Pereira, and Catarina Resende Oliveira, "Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease." *Free Radical Biology and Medicine*, vol 44, no. 12, 2008, pp. 2051-7.
- [96] Apelt, Jenny, Marina Bigl, Patrick Wunderlich, and Reinhard Schliebs, "Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology." *International Journal of Developmental Neuroscience*, vol 22, no. 7, 2004, pp. 475-84.
- [97] Jo, Dong-Gyu, Thiruma V. Arumugam, Ha-Na Woo, Jong-Sung Park, Sung-Chun Tang, Mohamed Mughal, Dong-Hoon Hyun et al. "Evidence that γ -secretase mediates oxidative stress-induced β -secretase expression in Alzheimer's disease." *Neurobiology of aging*, vol 31, no. 6, 2010, pp. 917-25.
- [98] Oda, Akiko, Akira Tamaoka, and Wataru Araki, "Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells." *Journal of neuroscience research*, vol 88, no. 5, 2010, pp. 1137-45.
- [99] Reddy, P. Hemachandra, Maria Manczak, Peizhong Mao, Marcus J. Calkins, Arubala P. Reddy, and Ulziibat Shirendeb, "Amyloid- β and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline." *Journal of Alzheimer's disease*, vol 20, no. s2, 2010, S499-512.
- [100] Sultana, Rukhsana, Debra Boyd-Kimball, H. Fai Poon, Jain Cai, William M. Pierce, Jon B. Klein, William R. Markesbery, Xiao Zhen Zhou, Kun Ping Lu, and D. Allan Butterfield, "Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis." *Neurobiology of aging*, vol 27, no. 7, 2006, pp. 918-25.
- [101] Butterfield, D. Allan, Marzia Perluigi, and Rukhsana Sultana, "Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics." *European journal of pharmacology*, vol 545, no. 1, 2006, pp. 39-50.
- [102] Grundke-Iqbal, Inge, Khalid Iqbal, Yunn-Chyn Tung, Maureen Quinlan, Henryk M. Wisniewski, and Lester I. Binder, "Abnormal phosphorylation of the microtubule-associated protein tau (τ) in Alzheimer cytoskeletal pathology." *Proceedings of the National Academy of Sciences* 83, no. 13, 1986, pp. 4913-7.
- [103] Iqbal, Khalid, Alejandra del C. Alonso, She Chen, M. Omar Chohan, Ezzat El-Akkad, Cheng-Xin Gong, Sabiha Khatoun et al. "Tau pathology in Alzheimer disease and other tauopathies." *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, vol 1739, no. 2-3, 2005, pp. 198-210.
- [104] Suzanne M., "Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease." *Drugs* 72, no. 1, 2012, pp. 49-66.
- [105] Calvo-Ochoa, Erika, Karina Hernández-Ortega, Patricia Ferrera, Sumiko Morimoto, and Clorinda Arias, "Short-term high-fat-and-fructose feeding produces insulin signaling alterations accompanied by neurite and synaptic reduction and astroglial activation in the rat hippocampus." *Journal of Cerebral Blood Flow & Metabolism*, vol 34, no. 6 (2014), pp. 1001-8.
- [106] Ramos-Rodríguez, Juan Jose, Sara Molina-Gil, Oscar Ortiz-Barajas, Margarita Jimenez-Palomares, German Perdomo, Irene Cozar-Castellano, Alfonso Maria Lechuga-Sancho, and Monica Garcia-Alloza, "Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models." *PLoS One*, vol 9, no. 2, 2014, e89229.
- [107] Selkoe, Dennis J., "Resolving controversies on the path to Alzheimer's therapeutics." *Nature medicine* 17, no. 9, 2011, pp. 1060.
- [108] Cole, Greg M., and Sally A. Frautschy, "The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease." *Experimental gerontology* 42, no. 1-2, 2007, pp. 10-21.
- [109] Freiher, Jessica, Manfred Hallschmid, William H. Frey, Yvonne F. Brünner, Colin D. Chapman, Christian Hölscher, Suzanne Craft, Fernanda G. De Felice, and Christian Benedict, "Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence." *CNS drugs*, vol 27, no. 7, 2013, pp. 505-14.
- [110] Benedict, Christian, William H. Frey II, Helgi B. Schiöth, Bernd Schultes, Jan Born, and Manfred Hallschmid, "Intranasal insulin as a therapeutic option in the treatment of cognitive impairments." *Experimental gerontology*, vol 46, no. 2-3, 2011, pp. 112-5.
- [111] Reger, M. A., G. S. Watson, W. H. Frey II, L. D. Baker, B. Cholerton, M. L. Keeling, D. A. Belongia et al. "Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype." *Neurobiology of aging*, vol 27, no. 3, 2006, pp. 451-8.
- [112] Reger, Mark A., G. Watson, Pattie S. Green, Laura D. Baker, Brenna Cholerton, Mark A. Fishel, Stephen R. Plymate et al. "Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid- β in memory-impaired older adults." *Journal of Alzheimer's disease*, vol 13, no. 3, 2008, pp. 323-31.
- [113] Kim, Bhumsoo, and Eva L. Feldman, "Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome." *Experimental & molecular medicine*, vol 47, no. 3, 2015, e149.
- [114] McIntyre, Roger S., Alissa M. Powell, Oksana Kaidanovich-Beilin, Joanna K. Soczynska, Mohammad Alsuwaidan, Hanna O. Woldeyohannes, Ashley S. Kim, and L. Ashley Gallagher, "The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders." *Behavioural brain research*

- 237, 2013, pp. 164-71.
- [115] Corbett, Anne, James Pickett, Alistair Burns, Jonathan Corcoran, Stephen B. Dunnett, Paul Edison, Jim J. Hagan et al. "Drug repositioning for Alzheimer's disease." *Nature Reviews Drug Discovery*, vol 11, no. 11, 2012, pp. 833.
- [116] Abbas T, Faivre E, Hölscher C., "Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease", *Behav Brain Res*, 2009, pp. 265-71.
- [117] Yusta, Bernardo, Laurie L. Baggio, Jennifer L. Estall, Jackie A. Koehler, Dianne P. Holland, Hongyun Li, Danny Pipeleers, Zhidong Ling, and Daniel J. Drucker, "GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress." *Cell metabolism*, vol 4, no. 5, 2006, pp. 391-406.
- [118] Hunter, Kerry, and Christian Hölscher, "Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis." *BMC neuroscience*, vol 13, no. 1, 2012, pp. 33.
- [119] Fernanda G. De Felice*, Mychael V. Lourenco, Sergio T. Ferreira, "How does brain insulin resistance develop in Alzheimer's disease?", *Alzheimer's & Dementia*, vol 10, 2014, pp. S26-32.
- [120] Han, Wei-Na, Christian Hölscher, Li Yuan, Wei Yang, Xiao-Hui Wang, Mei-Na Wu, and Jin-Shun Qi, "Liraglutide protects against amyloid- β protein-induced impairment of spatial learning and memory in rats." *Neurobiology of aging*, vol 34, no. 2, 2013, pp. 576-88.
- [121] McClean, Paula L., Vadivel Parthasarathy, Emilie Faivre, and Christian Hölscher, "The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease." *Journal of Neuroscience*, vol 31, no. 17, 2011, pp. 6587-94.
- [122] Kim, Bhumsoo, and Eva L. Feldman, "Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome." *Experimental & molecular medicine*, vol 47, no. 3, 2015, e149.
- [123] Imfeld, Patrick, Michael Bodmer, Susan S. Jick, and Christoph R. Meier, "Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer's disease: A Population-Based Case-Control Study." *Journal of the American Geriatrics Society*, vol 60, no. 5, 2012, pp. 916-21.
- [124] Miller, Benjamin W., Kristine C. Willett, and Alicia R. Desilets, "Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease." *Annals of Pharmacotherapy*, vol 45, no. 11, 2011, pp. 1416-24.